Oct 30, 2026 · 2 min read
Otsuka lifts annual profit guide as new kidney drug offsets US generic hit
Otsuka Holdings lifted its year-to-December core profit forecast to ¥500bn from ¥470bn, with a newly launched IgA nephropathy drug and its antipsychotic offsetting a 31.1% nine-month sales fall in its kidney-disease drug after US generic entry.